Please use this identifier to cite or link to this item:
Title: Artemether-lumefantrine versus chloroquine for the treatment of uncomplicated Plasmodium knowlesi malaria : an open-label randomized controlled trial CAN KNOW
Authors: Grigg, Matthew J.
William, Timothy
Barber, Bridget E.
Rajahram, Giri S.
Menon, Jayaram
Schimann, Emma
Wilkes, Christopher S.
Patel, Kaajal
Chandna, Arjun
Price, Ric N.
Yeo, Tsin Wen
Anstey, Nicholas M.
Keywords: Science::Medicine
Issue Date: 2017
Source: Grigg, M. J., William, T., Barber, B. E., Rajahram, G. S., Menon, J., Schimann, E., . . . Anstey, N. M. (2018). Artemether-lumefantrine versus chloroquine for the treatment of uncomplicated Plasmodium knowlesi malaria : an open-label randomized controlled trial CAN KNOW. Clinical Infectious Diseases, 66(2), 229-236. doi:10.1093/cid/cix779
Journal: Clinical Infectious Diseases
Abstract: Background: Plasmodium knowlesi is reported increasingly across Southeast Asia and is the most common cause of malaria in Malaysia. No randomized trials have assessed the comparative efficacy of artemether-lumefantrine (AL) for knowlesi malaria. Methods: A randomized controlled trial was conducted in 3 district hospitals in Sabah, Malaysia to compare the efficacy of AL against chloroquine (CQ) for uncomplicated knowlesi malaria. Participants were included if they weighed >10 kg, had a parasitemia count <20000/μL, and had a negative rapid diagnostic test result for Plasmodium falciparum histidine-rich protein 2. Diagnosis was confirmed by means of polymerase chain reaction. Patients were block randomized to AL (total target dose, 12 mg/kg for artemether and 60 mg/kg for lumefantrine) or CQ (25 mg/kg). The primary outcome was parasite clearance at 24 hours in a modified intention-to-treat analysis. Results: From November 2014 to January 2016, a total of 123 patients (including 18 children) were enrolled. At 24 hours after treatment 76% of patients administered AL (95% confidence interval [CI], 63%–86%; 44 of 58) were aparasitemic, compared with 60% administered CQ (47%–72%; 39 of 65; risk ratio, 1.3 [95% CI, 1.0–1.6]; P = .06). Overall parasite clearance was shorter after AL than after CQ (median, 18 vs 24 hours, respectively; P = .02), with all patients aparasitemic by 48 hours. By day 42 there were no treatment failures. The risk of anemia during follow-up was similar between arms. Patients treated with AL would require lower bed occupancy than those treated with CQ (2414 vs 2800 days per 1000 patients; incidence rate ratio, 0.86 [95% CI, .82–.91]; P < .001). There were no serious adverse events. Conclusions: AL is highly efficacious for treating uncomplicated knowlesi malaria; its excellent tolerability and rapid therapeutic response allow earlier hospital discharge, and support its use as a first-line artemisinin-combination treatment policy for all Plasmodium species in Malaysia.
ISSN: 1058-4838
DOI: 10.1093/cid/cix779
Rights: © 2017 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
cix779.pdf347.31 kBAdobe PDFThumbnail


Updated on Jan 23, 2021


Updated on Jan 24, 2021

Page view(s)

Updated on Jan 25, 2021


Updated on Jan 25, 2021

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.